{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:52:01Z","timestamp":1791503521401,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.resinv.2026.101492","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:12:29Z","timestamp":1785186749000},"page":"101492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nintedanib for non-IPF progressive pulmonary fibrosis: A systematic review and narrative synthesis of real-world effectiveness and safety"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-329X","authenticated-orcid":false,"given":"Narat","family":"Srivali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3504-1633","authenticated-orcid":false,"given":"Federica","family":"De Giacomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2026.101492_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2026.101492_bib2","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2026.101492_bib3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101492_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00085-2020","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"55","author":"Brown","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101492_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"20","author":"Kolb","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2026.101492_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02571-2021","article-title":"Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry","volume":"60","author":"Hambly","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101492_bib7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.resinv.2026.101492_bib8","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101492_bib9","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2026.101492_bib10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2026.101492_bib11","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.resinv.2026.101492_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.resinv.2026.101492_bib13","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.resinv.2026.101492_bib14","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin Epidemiol Glob Health"},{"key":"10.1016\/j.resinv.2026.101492_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12890-019-0937-0","article-title":"Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases","volume":"19","author":"Torrisi","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2026.101492_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00529-2023","article-title":"Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK","volume":"10","author":"Dixon","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2026.101492_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.medcli.2025.107169","article-title":"Real-world use of nintedanib for the treatment of interstitial lung disease with progressive pulmonary fibrosis","volume":"165","author":"Cabrera C\u00e9sar","year":"2025","journal-title":"Med Clin"},{"key":"10.1016\/j.resinv.2026.101492_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00423-2022","article-title":"Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study","volume":"9","author":"Raman","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2026.101492_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002850","article-title":"Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study","volume":"9","author":"Campochiaro","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.resinv.2026.101492_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00408-025-00832-4","article-title":"Effectiveness of nintedanib in progressive pulmonary fibrosis assessed by progression criteria: an Italian, observational, multicenter study","volume":"203","author":"Mondoni","year":"2025","journal-title":"Lung"},{"key":"10.1016\/j.resinv.2026.101492_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-097246","article-title":"Characterisation of patients with antifibrotic-treated non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis: a retrospective real-life study","volume":"15","author":"Renner","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.resinv.2026.101492_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00408-024-00778-z","article-title":"Continued treatment with nintedanib in patients with progressive pulmonary fibrosis: data from INBUILD-ON","volume":"203","author":"Wuyts","year":"2025","journal-title":"Lung"},{"key":"10.1016\/j.resinv.2026.101492_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005086","article-title":"Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON","volume":"11","author":"Allanore","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.resinv.2026.101492_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00926-2024","article-title":"Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry","volume":"11","author":"Behr","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2026.101492_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04587-2020","article-title":"Effects of nintedanib by inclusion criteria for progression of interstitial lung disease","volume":"59","author":"Maher","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2026.101492_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526001267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534526001267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:25:23Z","timestamp":1791501923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534526001267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2212534526001267"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101492","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nintedanib for non-IPF progressive pulmonary fibrosis: A systematic review and narrative synthesis of real-world effectiveness and safety","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2026.101492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101492"}}